Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2008;336:1032 (10 May), doi:10.1136/bmj.39554.346759.BE
Is cheap and effective, yet its availability remains restricted
| The first 150 words of the full text of this article appear below. |
An evidence based guideline on the use of misoprostol for womens reproductive health has recently been published.1 It underlines the value of misoprostol for specific clinical indications in obstetrics and gynaecology despite the remarkable absence of marketing efforts by producers. Misoprostol is a prostaglandin E1 analogue, which is effective, cheap, and can be used safely for a variety of obstetric and gynaecological indications.2 It is rare that a new drug can potentially save tens of thousands of maternal lives, particularly in the poorest countries in the world.
The uterotonic action of misoprostol was discovered as a side effect of its main intended use of treating peptic ulcer.3 For more than 20 years it has been a focus of global interest among obstetricians and gynaecologists, although the patent holder consistently refuses to acknowledge its tremendous potential value for women in the poorest countries. The reasons for this refusal seem to be
Staffan Bergström, professor1, Annette Aronsson, senior obstetrician2
1 AMDD Program, Columbia University, New York, NY 10032, USA, 2 Division of International Health, Karolinska Institutet, SE-171 76 Stockholm, Sweden
Staffan.Bergstrom@ki.se
Read all Rapid Responses